Literature DB >> 11689220

The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men.

G Eiriksdottir1, M K Bolla, B Thorsson, G Sigurdsson, S E Humphries, V Gudnason.   

Abstract

The aim of this study was to examine whether the well-established effect of the common TaqIB polymorphism in intron 1 of the gene for cholesterol ester transfer protein (CETP) on high density lipoprotein cholesterol (HDL-C) concentration and increased risk of myocardial infarction (MI), could be explained by the recently identified -629C>A functional polymorphism in the promoter. Non-fatal MI cases (388 male) and a control group of 794 healthy men were recruited from the 30 year long prospective Reykjavik Study. In the healthy men the frequency of the TaqIB B2 allele was 0.47 (95% CI: 0.44-0.50) and there was a strong allelic association with the -629A allele (D=-0.21, P<0.0001), which had a frequency of 0.52 (95% CI: 0.49-0.56). B2B2 homozygotes displayed 15% higher HDL-C levels than subjects homozygous for the B1 allele (P<0.0001). Homozygotes for the -629A allele displayed 14% higher HDL-C concentrations than subjects homozygous for the -629C allele (P<0.0001). The frequencies of the alleles associated with lower HDL-C were significantly higher in cases compared with controls, 0.59 versus 0.53 (TaqIB B1) and 0.52 versus 0.48 (-629 C) respectively (P<0.05 for both). There was a significantly higher risk for MI in B1B1 homozygotes (OR=1.44, 95% CI: 1.10-1.87, P<0.01), compared to the other genotypes combined. This was not observed for the CC homozygotes (OR=1.16, 95% CI: 0.87-1.54). In addition, homozygotes for the TaqI B2 allele experienced a first MI 2 years later than men with other genotypes, 59 versus 61 years (P<0.05). This effect was not seen for the promoter polymorphism. These results strongly confirm the role of the CETP gene and the TaqIB variant as a risk factor for MI and suggest that another functional polymorphism is yet to be discovered in the CETP gene, that will explain the effect on MI associated with TaqIB observed in this study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689220     DOI: 10.1016/s0021-9150(01)00489-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  Cholesteryl ester transfer protein (CETP) -629C/A polymorphism and it's effects on the serum lipid levels in metabolic syndrome patients.

Authors:  M Akbarzadeh; T Hassanzadeh; M Saidijam; R Esmaeili; Sh Borzouei; M Hajilooi; H Mahjub; M Paoli
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  TaqIB and severity of coronary artery disease in the Turkish population: a pilot study.

Authors:  Dilara Kaman; Necip İlhan; Nevin İlhan; Mehmet Akbulut
Journal:  Bosn J Basic Med Sci       Date:  2015-02-01       Impact factor: 3.363

3.  Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism.

Authors:  Hong Lu; Akihiro Inazu; Yuri Moriyama; Toshinori Higashikata; Masa-Aki Kawashiri; Wenxin Yu; Zhiping Huang; Tomonori Okamura; Hiroshi Mabuchi
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

4.  Genetic variants at the APOE, lipoprotein lipase (LpL), cholesteryl ester transfer protein (CETP), and endothelial nitric oxide (eNOS) genes and coronary artery disease (CAD): CETP Taq1 B2B2 associates with lower risk of CAD in Asian Indians.

Authors:  Aparna Amarendra Bhanushali; Bibhu R Das
Journal:  J Community Genet       Date:  2010-03-25

Review 5.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Authors:  Eva Boes; Stefan Coassin; Barbara Kollerits; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-11-17       Impact factor: 4.032

6.  Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease.

Authors:  Pamela A McCaskie; John P Beilby; Caroline M L Chapman; Joseph Hung; Brendan M McQuillan; Peter L Thompson; Lyle J Palmer
Journal:  Hum Genet       Date:  2007-02-08       Impact factor: 4.132

7.  Associations of genetic variants in ATP-binding cassette A1 and cholesteryl ester transfer protein and differences in lipoprotein subclasses in the multi-ethnic study of atherosclerosis.

Authors:  Michael Y Tsai; Na Li; A Richey Sharrett; Steven Shea; David R Jacobs; Russell Tracy; Donna Arnett; Valerie Arends; Wendy Post
Journal:  Clin Chem       Date:  2009-01-08       Impact factor: 8.327

Review 8.  Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.

Authors:  Michael J Sorich; Michael D Wiese; Rebekah L O'Shea; Brita Pekarsky
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 9.  HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics.

Authors:  Cecilia Vitali; Sumeet A Khetarpal; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2017-11-04       Impact factor: 2.931

10.  Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Michael Y Tsai; Craig Johnson; W H Linda Kao; A Richey Sharrett; Valerie L Arends; Richard Kronmal; Nancy Swords Jenny; David R Jacobs; Donna Arnett; Daniel O'Leary; Wendy Post
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.